ARHGEF10

Across TCGA pan-cancer cohorts, ARHGEF10 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ARHGEF10’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ARHGEF10 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ARHGEF10 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

CCRCC, LSCC, and LUAD are the cancer types where ARHGEF10 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGEF10 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+0.725	<.001	12	view →
LSCC	Female	All	−1.032	<.001	9	view →
LUAD	Female	III,IV	−0.878	<.001	9	view →
COAD	All	II,III,IV	−0.406	<.001	9	view →
PDAC	Female	All	+0.378	<.001	6	view →
OV	All	All	−0.550	.003	2	view →
HNSC	Male	All	−0.101	.041	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ARHGEF10–CCRCC

Open the CCRCC breakdown →